Paris ALS Center

Hôpital de la Salpêtrière

The Paris ALS Center was created by Pr Vincent Meininger. It is devoted to the diagnosis and care of patients with ALS and other motor neuron diseases.

Hôpital de la Salpêtrière

To understand the disease mechanisms at work in ALS, our first objective was to perform clinical research and study the natural disease course of ALS. This strategy led to the first successful clinical trial in 1994. Beside our current involvement with clinical trials, we acquired an expertise in muscle biomarkers, genetics and neuroimaging.

Contact
Location
Hôpital de la Salpêtrière, Boulevard de l'Hopital, Paris, France

Our Specialists

François Salachas

Coordinator and Investigator of research

Dr. François Salachas is Coordinator and Investigator of research in Hôpital Pitié-Salpêtrière.

François Salachas
Current trials
Recruiting
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Recruiting
Phase iii

ADORE Trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Recruiting
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more